[{"Assets_0_Q3_USD":176683000.0,"CommonStockSharesOutstanding_0_Q3_shares":24034988.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-13450000.0,"NetIncomeLoss_1_Q3_USD":-7588000.0,"NetIncomeLoss_3_Q3_USD":-18620000.0,"StockholdersEquity_0_Q3_USD":167523000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":548000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":1647000.0,"Ticker":"CRNX","CIK":"1658247","name":"CRINETICS PHARMACEUTICALS, INC.","OfficialName":"Crinetics Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1104302360.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20181113"}]